Listed

Dogecoin Cash, Inc.: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Aug 19, 2025 and accepted by EDGAR at Aug 19, 2025, 16:56 ET.

Share

Management's discussion and analysis

As filed, 6,085 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Certain statements in this Report constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Factors that might cause such a difference include, among others, uncertainties relating to general economic and business conditions; industry trends; changes in demand for our products and services; uncertainties relating to customer plans and commitments and the timing of orders received from customers; announcements or changes in our pricing policies or that of our competitors; unanticipated delays in the development, market acceptance or installation of our products and services; changes in government regulations; availability of management and other key personnel; availability, terms, and deployment of capital; relationships with third-party equipment suppliers; and worldwide political stability and economic growth. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

Results of Operations

Three Months Ended June 30, 2025 compared with the Three Months Ended June 30, 2024

2025 Three Months Ended A June 30, 2024 B June 30, A-B Change Change %
REVENUE $192,464 $234,391 $(41,927) (18)%
Cost of revenues 70,988 84,102 (13,114) (16)%
Cost of sales % of total sales 37% 36% 1% 3%
Gross profit 121,476 150,289 (28,813) (19)%
Gross profit % of sales 63% 64%
EXPENSES
Professional fees 41,052 91,597 (50,545) (55)%
Depreciation and amortization 302 302 –– ––%
Wages and salaries 76,027 97,009 (20,982) (22)%
Advertising 638 6,052 (5,414) (89)%
General and administrative 186,873 153,274 33,599 22%
Total expenses 304,892 348,234 (43,342) (12)%
NET LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS (183,416) (197,945) 14,529 (7)%

Revenue for the three months ended June 30, 2025, decreased 18% compared to the three months ended June 30, 2024. Cost of revenues as a percentage of sales decreased 16% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2025.

Total operating expenses decreased in June 30, 2025 compared with 2024 which trended down as did revenue in the current period. Decreases in professional fees, wages and salaries, advertising and general and administrative expenses. PrestoDoctor management salaries also decreased during the three months ended June 30, 2025.

Six Months Ended June 30, 2025 compared with the Six Months Ended June 30, 2024

2025 Three Months Ended A June 30, 2024 B June 30, A-B Change Change %
REVENUE $376,937 $459,522 $(82,585) (18)%
Cost of revenues 138,494 183,120 (44,626) (24)%
Cost of sales % of total sales 37% 40% (3)% (8)%
Gross profit 238,443 276,402 (37,959) (14)%
Gross profit % of sales 63% 60%
EXPENSES
Professional fees 78,912 149,234 (70,322) (47)%
Depreciation and amortization 603 2,727 (2,124) (78)%
Wages and salaries 149,417 211,080 (61,633) (29)%
Advertising 2,499 7,932 (5,433) (68)%
General and administrative 292,042 278,165 13,877 5%
Total expenses 523,473 649,138 (125,665) (19)%
NET LOSS FOR THE PERIOD FROM CONTINUING OPERATIONS (285,030) (372,736) 87,706 (24)%

Revenue for the six months ended June 30, 2025, decreased 18% compared to the six months ended June 30, 2024. Cost of revenues as a percentage of sales decreased 8% between the periods. The decrease in revenues is primarily a result of the significant increase in competition for market share in the cannabis tele-medicine industry. This decrease in the demand for our service continued during the second quarter of 2025.

Total operating expenses decreased in June 30, 2025 compared with 2024 which trended down as did revenue in the current period. Decreases in professional fees, depreciation & amortization, wages and salaries, advertising and general and administrative expenses. PrestoDoctor management salaries also decreased during the six months ended June 30, 2025.

Liquidity and Capital Resources

Cash provided by operating activities was $5,208 in the six months ended June 30, 2025. We ended the second quarter of 2025 with $50,848 in cash on hand.

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. We incurred net losses of $7,402,698 and $613,344, respectively, for the six months ended June 30, 2025 and 2024 and had an accumulated deficit of $84,132,677 as of June 30, 2025. The Company may seek to raise money for working capital purposes through a public offering of its equity capital or through a private placement of equity capital or convertible debt. It will be important for the Company to be successful in its efforts to raise capital in this manner if it is going to be able to further its business plan in an aggressive manner. Raising capital in this manner will cause dilution to current shareholders.

The amount of cash on hand the Company has does not provide sufficient liquidity to meet the immediate needs of our current operations.

Off Balance Sheet Arrangements

None

Controls and procedures

As filed, 1,824 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

Conclusions of Management Regarding Effectiveness of Disclosure Controls and Procedures

At the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company’s management, including the Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of the design and operations of the Company’s disclosure controls and procedures (as defined in Rule 13a – 15(e) and Rule 15d – 15(e) under the Exchange Act). Based on that evaluation, the CEO and the CFO have concluded that as of the end of the period covered by this report, the Company’s disclosure controls and procedures were not effective as it was determined that there were material weaknesses affecting our disclosure controls and procedures.

Management of the Company believes that these material weaknesses are due to the small size of the company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As the Company grows, management expects to increase the number of employees, which will enable us to implement adequate segregation of duties within the internal control framework.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting during the quarter ended June 30, 2025, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$192.5kus-gaap:Revenues
Revenue6 months2025-01-01 to 2025-06-30$376.9kus-gaap:Revenues
Cost of revenue3 months2025-04-01 to 2025-06-30$71.0kus-gaap:CostOfRevenue
Cost of revenue6 months2025-01-01 to 2025-06-30$138.5kus-gaap:CostOfRevenue
Gross profit3 months2025-04-01 to 2025-06-30$121.5kus-gaap:GrossProfit
Gross profit6 months2025-01-01 to 2025-06-30$238.4kus-gaap:GrossProfit
Operating income3 months2025-04-01 to 2025-06-30−$183.4kus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30−$285.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2025-04-01 to 2025-06-30$11.9kus-gaap:InterestExpense
Interest expense6 months2025-01-01 to 2025-06-30$21.6kus-gaap:InterestExpense
Income tax3 months2025-04-01 to 2025-06-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-01-01 to 2025-06-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-04-01 to 2025-06-30−$7.3mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30−$7.4mus-gaap:NetIncomeLoss
Operating cash flow6 months2025-01-01 to 2025-06-30$5.2kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2025-06-30$50.8kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$792.7kus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$2.1mus-gaap:Assets
Current liabilitiesAt period end2025-06-30$781.6kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-06-30$2.1mus-gaap:Liabilities
Shareholders' equityAt period end2025-06-30−$1.7mus-gaap:StockholdersEquity
Shares outstandingAt period end2025-06-30148,947,864 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001096906-25-001380. Last ingested by Listed: Oct 24, 2026, 15:11 ET. Listed shows no prices and gives no investment advice.